{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T21:27:33Z","timestamp":1793482053271,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier","isbn-type":[{"value":"9780128152133","type":"print"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1016\/bs.pmch.2017.12.002","type":"book-chapter","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T05:41:55Z","timestamp":1520487715000},"page":"87-111","source":"Crossref","is-referenced-by-count":33,"title":["VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine)"],"prefix":"10.1016","author":[{"given":"Nicole D.","family":"Harriott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan B.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haig P.","family":"Bozigian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri E.","family":"Grigoriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/bs.pmch.2017.12.002_bb0010","doi-asserted-by":"crossref","first-page":"10993","DOI":"10.1073\/pnas.89.22.10993","article-title":"Expression cloning of a reserpine-sensitive vesicular monoamine transporter","volume":"89","author":"Erickson","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/bs.pmch.2017.12.002_bb0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1146\/annurev.neuro.20.1.125","article-title":"The role of vesicular transport proteins in synaptic transmission and neural degeneration","volume":"20","author":"Liu","year":"1997","journal-title":"Annu Rev Neurosci"},{"issue":"10","key":"10.1016\/bs.pmch.2017.12.002_bb0020","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1073\/pnas.93.10.5166","article-title":"Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter","volume":"93","author":"Erickson","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/bs.pmch.2017.12.002_bb0025","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/med.20187","article-title":"Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry","volume":"31","author":"Wimalasena","year":"2011","journal-title":"Med Res Rev"},{"issue":"1","key":"10.1016\/bs.pmch.2017.12.002_bb0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ejn.13357","article-title":"Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease","volume":"45","author":"Lohr","year":"2017","journal-title":"Eur J Neurosci"},{"issue":"15","key":"10.1016\/bs.pmch.2017.12.002_bb0035","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1096\/fj.00-0203rev","article-title":"Transport mechanisms in acetylcholine and monoamine storage","volume":"14","author":"Parsons","year":"2000","journal-title":"FASEB J"},{"issue":"5","key":"10.1016\/bs.pmch.2017.12.002_bb0040","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0197-0186(02)00058-X","article-title":"Microscopic kinetics and structure-function analysis in the vesicular acetylcholine transporter","volume":"41","author":"Bravo","year":"2002","journal-title":"Neurochem Int"},{"issue":"19","key":"10.1016\/bs.pmch.2017.12.002_bb0045","doi-asserted-by":"crossref","first-page":"8773","DOI":"10.1073\/pnas.92.19.8773","article-title":"The vesicular monoamine transporter 2 is present in small synaptic vesicles and preferentially localizes to large dense core vesicles in rat solitary tract nuclei","volume":"92","author":"Nirenberg","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"10.1016\/bs.pmch.2017.12.002_bb0050","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1523\/JNEUROSCI.16-13-04135.1996","article-title":"Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine","volume":"16","author":"Nirenberg","year":"1996","journal-title":"J Neurosci"},{"issue":"11","key":"10.1016\/bs.pmch.2017.12.002_bb0055","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1523\/JNEUROSCI.17-11-04037.1997","article-title":"Immunogold localization of the dopamine transporter: an ultrastructural study of the rat ventral tegmental area","volume":"17","author":"Nirenberg","year":"1997","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/bs.pmch.2017.12.002_bb0060","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/(SICI)1098-2396(199706)26:2<194::AID-SYN10>3.0.CO;2-Y","article-title":"Vesicular monoamine transporter-2: immunogold localization in striatal axons and terminals","volume":"26","author":"Nirenberg","year":"1997","journal-title":"Synapse"},{"issue":"3","key":"10.1016\/bs.pmch.2017.12.002_bb0065","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0959-4388(98)80068-8","article-title":"Vesicular neurotransmitter transport and the presynaptic regulation of quantal size","volume":"8","author":"Reimer","year":"1998","journal-title":"Curr Opin Neurobiol"},{"issue":"2","key":"10.1016\/bs.pmch.2017.12.002_bb0070","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1023\/A:1020573325823","article-title":"Bioenergetics of neurotransmitter transport","volume":"30","author":"Rudnick","year":"1998","journal-title":"J Bioenerg Biomembr"},{"issue":"3","key":"10.1016\/bs.pmch.2017.12.002_bb0075","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1021\/bi00455a002","article-title":"Energetics of reserpine binding and occlusion by the chromaffin granule biogenic amine transporter","volume":"29","author":"Rudnick","year":"1990","journal-title":"Biochemistry"},{"key":"10.1016\/bs.pmch.2017.12.002_bb0080","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/B978-0-444-63425-2.00010-6","article-title":"The role of dopamine in Huntington's disease","volume":"211","author":"Cepeda","year":"2014","journal-title":"Prog Brain Res"},{"issue":"Suppl. 2","key":"10.1016\/bs.pmch.2017.12.002_bb0085","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.51.2_Suppl_2.S2","article-title":"Biochemical aspects of Parkinson's disease","volume":"51","author":"Hornykiewicz","year":"1998","journal-title":"Neurology"},{"issue":"27","key":"10.1016\/bs.pmch.2017.12.002_bb0090","article-title":"Current concepts on the physiopathological relevance of dopaminergic receptors","volume":"11","author":"Ledonne","year":"2017","journal-title":"Front Cell Neurosci"},{"issue":"18","key":"10.1016\/bs.pmch.2017.12.002_bb0095","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1080\/14656566.2016.1258063","article-title":"Dopamine depleters in the treatment of hyperkinetic movement disorders","volume":"17","author":"Jankovic","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/bs.pmch.2017.12.002_bb0100","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/BF02167633","article-title":"Rauwolfia alkaloids. VII. The constitution of reserpine from Rauwolfia serpentina","volume":"9","author":"Dorfman","year":"1953","journal-title":"Experientia"},{"issue":"12","key":"10.1016\/bs.pmch.2017.12.002_bb0105","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1021\/cr050521a","article-title":"Reserpine: a challenge for total synthesis of natural products","volume":"105","author":"Chen","year":"2005","journal-title":"Chem Rev"},{"key":"10.1016\/bs.pmch.2017.12.002_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0040-4020(58)88022-9","article-title":"Total synthesis of reserpine","volume":"2","author":"Woodward","year":"1958","journal-title":"Tetrahedron"},{"issue":"19","key":"10.1016\/bs.pmch.2017.12.002_bb0115","doi-asserted-by":"crossref","first-page":"9074","DOI":"10.1073\/pnas.89.19.9074","article-title":"Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium","volume":"89","author":"Liu","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/bs.pmch.2017.12.002_bb0120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0021-9258(18)54110-7","article-title":"Reserpine binding to a vesicular amine transporter expressed in Chinese hamster ovary fibroblasts","volume":"268","author":"Schuldiner","year":"1993","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/bs.pmch.2017.12.002_bb0125","doi-asserted-by":"crossref","first-page":"7231","DOI":"10.1016\/S0021-9258(17)37272-1","article-title":"The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors","volume":"269","author":"Peter","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2017.12.002_bb0130","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/cber.19210540812","article-title":"Alkaloids of the lobelia plant. I. (Preliminary communication.)","volume":"54B","author":"Wieland","year":"1921","journal-title":"Ber Dtsch Chem Ges B"},{"key":"10.1016\/bs.pmch.2017.12.002_bb0135","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/jlac.19254440104","article-title":"Lobelia alkaloids II","volume":"444","author":"Wieland","year":"1925","journal-title":"Ann Chem"},{"issue":"2","key":"10.1016\/bs.pmch.2017.12.002_bb0140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0006-2952(01)00899-1","article-title":"A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse","volume":"63","author":"Dwoskin","year":"2002","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/bs.pmch.2017.12.002_bb0145","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0022-3565(24)36807-7","article-title":"Pharmacology of lobeline, a nicotinic receptor ligand","volume":"282","author":"Damaj","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"10.1016\/bs.pmch.2017.12.002_bb0150","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/0028-3908(90)90022-J","article-title":"Behavioral and pharmacokinetic studies on nicotine, cytisine and lobeline","volume":"29","author":"Reavill","year":"1990","journal-title":"Neuropharmacology"},{"issue":"13","key":"10.1016\/bs.pmch.2017.12.002_bb0155","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/S0028-3908(00)00140-4","article-title":"Lobeline inhibits nicotine-evoked [3H]dopamine overflow from rat striatal slices and nicotine-evoked 86Rb+ efflux from thalamic synaptosomes","volume":"39","author":"Miller","year":"2000","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/bs.pmch.2017.12.002_bb0160","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1124\/jpet.104.068098","article-title":"Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters","volume":"310","author":"Miller","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"10.1016\/bs.pmch.2017.12.002_bb0165","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2174\/156802611795371332","article-title":"Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs. Potential pharmacotherapies for the treatment of psychostimulant abuse","volume":"11","author":"Crooks","year":"2011","journal-title":"Curr Top Med Chem"},{"issue":"24","key":"10.1016\/bs.pmch.2017.12.002_bb0170","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1016\/j.bmcl.2008.10.042","article-title":"Synthesis and evaluation of a series of homologues of lobelane at the vesicular monoamine transporter-2","volume":"18","author":"Zheng","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"issue":"20","key":"10.1016\/bs.pmch.2017.12.002_bb0175","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1016\/j.bmcl.2005.07.032","article-title":"Synthesis and evaluation of a series of tropane analogues as novel vesicular monoamine transporter-2 ligands","volume":"15","author":"Zheng","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"10.1016\/bs.pmch.2017.12.002_bb0180","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00213-012-2748-3","article-title":"The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats","volume":"224","author":"Alvers","year":"2012","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/bs.pmch.2017.12.002_bb0185","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00213-011-2488-9","article-title":"The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats","volume":"220","author":"Beckmann","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.pmch.2017.12.002_bb0190","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejphar.2016.12.016","article-title":"GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2","volume":"795","author":"Nickell","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/bs.pmch.2017.12.002_bb0195","series-title":"International review of neurobiology","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0074-7742(08)60024-0","article-title":"Benzoquinolizine derivatives: a new class of monoamine-decreasing drugs with psychotropic action","volume":"vol. 4","author":"Pletscher","year":"1962"},{"issue":"Suppl. 170","key":"10.1016\/bs.pmch.2017.12.002_bb0200","first-page":"1","article-title":"Tetrabenazine (Nitoman) in the treatment of psychoses. With a discussion on the central mode of action of tetrabenazine and reserpine","volume":"39","author":"Lingjaerde","year":"1963","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/bs.pmch.2017.12.002_bb0205","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1192\/bjp.107.447.287","article-title":"A comparison of tetrabenazine and chlorpromazine in chronic schizophrenia","volume":"107","author":"Ashcroft","year":"1961","journal-title":"J Ment Sci"},{"issue":"5","key":"10.1016\/bs.pmch.2017.12.002_bb0210","first-page":"545","article-title":"Tetrabenazine in the treatment of Huntington's disease","volume":"3","author":"Paleacu","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"10.1016\/bs.pmch.2017.12.002_bb0215","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.amjopharm.2010.08.006","article-title":"Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders","volume":"8","author":"Guay","year":"2010","journal-title":"Am J Geriatr Pharmacother"},{"issue":"1","key":"10.1016\/bs.pmch.2017.12.002_bb0220","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1021\/jm950117b","article-title":"In vitro and in vivo studies of benzoisoquinoline ligands for the brain synaptic vesicle monoamine transporter","volume":"39","author":"Lee","year":"1996","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/bs.pmch.2017.12.002_bb0225","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/(SICI)1520-636X(1997)9:1<59::AID-CHIR11>3.0.CO;2-P","article-title":"Absolute configuration of (+)-\u03b1-dihydrotetrabenazine, an active metabolite of tetrabenazine","volume":"9","author":"Kilbourn","year":"1997","journal-title":"Chirality"},{"issue":"2","key":"10.1016\/bs.pmch.2017.12.002_bb0230","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0090-9556(25)06690-5","article-title":"Pharmacokinetics of tetrabenazine and its major metabolite in man and rat","volume":"15","author":"Mehvar","year":"1987","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/bs.pmch.2017.12.002_bb0235","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/0006-2952(66)90031-1","article-title":"Metabolic studies of tetrabenazine, a psychotropic drug in animals and man","volume":"15","author":"Schwartz","year":"1966","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/bs.pmch.2017.12.002_bb0240","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.ejmech.2011.02.046","article-title":"Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors","volume":"46","author":"Yao","year":"2011","journal-title":"Eur J Med Chem"},{"key":"10.1016\/bs.pmch.2017.12.002_bb0245","unstructured":"Gano KW, inventor; Neurocrine Biosciences, Inc., USA, assignee. Preparation of pyrido[2,1-a]isoquinoline derivatives for treating hyperkinetic disorders patent WO2008058261A1. 2008."},{"key":"10.1016\/bs.pmch.2017.12.002_bb0250","unstructured":"Clarke I, Turtle R, Johnston G, inventors; Cambridge Laboratories Limited, UK; Tridgett R, assignee. Preparation of dihydrotetrabenazines with affinity for monoamine transporters for use in pharmaceutical compositions for the treatment of hyperkinetic disorders patent WO2005077946A1. 2005."},{"issue":"3","key":"10.1016\/bs.pmch.2017.12.002_bb0255","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1124\/jpet.116.239160","article-title":"Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites","volume":"361","author":"Grigoriadis","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/bs.pmch.2017.12.002_bb0260","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0014-2999(95)00162-E","article-title":"Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific","volume":"278","author":"Kilbourn","year":"1995","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"10.1016\/bs.pmch.2017.12.002_bb0265","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1021\/jm000407e","article-title":"Property-based design: optimization of drug absorption and pharmacokinetics","volume":"44","author":"van De Waterbeemd","year":"2001","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/bs.pmch.2017.12.002_bb0270","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1021\/jm0303812","article-title":"Lessons learned from marketed and investigational prodrugs","volume":"47","author":"Ettmayer","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2017.12.002_bb0275","unstructured":"Tetrabenazine (Xenazine tablets) [package insert]. Mississauga, Canada; Biovail Corporation; May 2008."},{"key":"10.1016\/bs.pmch.2017.12.002_bb0285","series-title":"Prescribing information","author":"Ingrezza","year":"2017"},{"issue":"3","key":"10.1016\/bs.pmch.2017.12.002_bb0290","first-page":"44","article-title":"Single dose and repeat once-daily dose safety, tolerability and pharmacokinetics of valbenazine in healthy male subjects","volume":"47","author":"Luo","year":"2017","journal-title":"Psychopharmacol Bull"},{"issue":"5","key":"10.1016\/bs.pmch.2017.12.002_bb0295","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","article-title":"KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia","volume":"174","author":"Hauser","year":"2017","journal-title":"Am J Psychiatry"},{"issue":"12","key":"10.1016\/bs.pmch.2017.12.002_bb0300","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/mds.26330","article-title":"NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"30","author":"O'Brien","year":"2015","journal-title":"Mov Disord"},{"issue":"9","key":"10.1016\/bs.pmch.2017.12.002_bb0305","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.4088\/JCP.17m11777","article-title":"The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year KINECT 3 extension study","volume":"78","author":"Factor","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/bs.pmch.2017.12.002_bb0310","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/bs.pmch.2017.12.002_bb0315","series-title":"Prescribing information","author":"Austedo","year":"2017"},{"issue":"3","key":"10.1016\/bs.pmch.2017.12.002_bb0320","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s40268-017-0202-z","article-title":"Differences in dihydrotetrabenazine isomer concentrations following administration of tetrabenazine and valbenazine","volume":"17","author":"Skor","year":"2017","journal-title":"Drugs R D"},{"key":"10.1016\/bs.pmch.2017.12.002_bb0325","series-title":"Prescribing information","author":"Xenazine","year":"2015"},{"key":"10.1016\/bs.pmch.2017.12.002_bb0330","article-title":"Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review","author":"Caroff","year":"2017","journal-title":"J Comp Eff Res"}],"container-title":["Progress in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079646817300231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079646817300231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T15:24:44Z","timestamp":1751469884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0079646817300231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9780128152133"],"references-count":64,"URL":"https:\/\/doi.org\/10.1016\/bs.pmch.2017.12.002","relation":{},"ISSN":["0079-6468"],"issn-type":[{"value":"0079-6468","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}